A new study has demonstrated that the frequency of second primary malignancies (SPMs) is no higher with CAR-T cell therapies than with previous standard-of-care strategies.

The authors found that T cell malignancies represented a small minority of adverse events at just 1.5%.

The paper ‘Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients’ was published in the journal Clinical Cancer Research.

In November 2023, the US Food and Drug Administration (FDA) announced an investigation into the safety of BCMA- or CD19-directed autologous CAR-T cell immunotherapies, following reports of T cell malignancies in these patients.

However, since then, a study of over 700 patients treated at Stanford Health Care in the US indicated that the risk is just 6.5% in the three years after therapy.

The European Medicines Agency (EMA) has also reduced daily hospital safety monitoring for patients following treatment with CAR-T cell therapies Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel).

CAR-T adverse events

To understand the frequency and subtypes of SPMs following CAR-T in lymphoma and myeloma, the authors of the new study conducted a literature search in the MEDLINE, Embase, and CENTRAL (Cochrane) databases.

They identified 326 SPMs across 5,517 patients from 18 clinical trials and seven real-world studies.

With a median follow-up of 21.7 months, the overall SPM point estimate was 5.8%. SPM estimates were associated with treatment setting, duration of follow-up, and number of prior treatment lines, which were each confirmed as independent study-level risk factors of SPM in a meta-regression model.

In a distribution analysis of SPM subtypes, haematologic malignancies were the most common (37%), followed by solid tumours (27%) and non-melanoma skin cancers (16%). T cell malignancies represented a small minority of events (1.5%).

The authors concluded: “These data raise awareness of SPM as a clinically relevant long-term adverse event in patients receiving CAR T-cell therapy. However, our findings do not indicate that SPM frequency is higher with CAR-T versus previous standard-of-care strategies.”

Diana Spencer, Senior Digital Content Editor, DDW